The impact of Althaea officinalis formulation on controlling the symptoms of atopic dermatitis
Phase 3
- Conditions
- Atopic Eczema.Other atopic dermatitis
- Registration Number
- IRCT2016102323235N5
- Lead Sponsor
- Vice chancellor for research, Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Confirm eczema atopic dermatitis by an allergist according to plan; family history of atopy; positive allergy tests (skin prick test) ; Complete the consent form
Exclusion criteria
Local sensitivity to new formulations; Patients with diseases of the skin; Systemic immunosuppressive drugs; Lack of cooperation during treatment; waste infections that require antibiotics or drug penetration increase; patients with atopic eczema lesions with high emissions (over 50%) of body surface
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The severity of the itch. Timepoint: monthly. Method of measurement: questionnaire.;Inflammation. Timepoint: monthly. Method of measurement: questionnaire.;The size of the lesion. Timepoint: monthly. Method of measurement: questionnaire.
- Secondary Outcome Measures
Name Time Method The severity of the itch. Timepoint: monthly. Method of measurement: questionnaire.;The inflammation. Timepoint: monthly. Method of measurement: questionnaire.;The size of the lesion. Timepoint: monthly. Method of measurement: questionnaire.